Skip to main content

Table 3 Duration of Response (Days)

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Response   Cohort 1 Cohort 2
Complete Response Mean (SD) 84 (93.8)
Median 56
Range 8–189 (ongoing)
Partial Response Mean (SD) 194 (180.0) 113 (103.0)
Median 118 133
Range 77–512 1–204
Stable Disease Mean (SD) 125 (156.8) 127 (186.3)
Median 56 63
Range 1–509 1–544